Pliant Therapeutics, Inc. (PLRX)
NASDAQ: PLRX · Real-Time Price · USD
1.210
0.00 (0.00%)
At close: Apr 28, 2026, 4:00 PM EDT
1.200
-0.010 (-0.83%)
After-hours: Apr 28, 2026, 4:09 PM EDT
Pliant Therapeutics Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
| FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
| Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| Revenue | - | - | 1.58 | 9.69 | 7.57 | |
| Revenue Growth (YoY) | - | - | -83.69% | 27.91% | -81.89% | |
| Gross Profit | - | - | 1.58 | 9.69 | 7.57 | |
| Selling, General & Admin | 45.92 | 59.06 | 57.93 | 39.95 | 27.56 | |
| Research & Development | 104.16 | 169.31 | 127.8 | 96.94 | 77.55 | |
| Operating Expenses | 150.07 | 228.37 | 185.73 | 136.89 | 105.11 | |
| Operating Income | -150.07 | -228.37 | -184.15 | -127.2 | -97.54 | |
| Interest Expense | -2.56 | -3.02 | -1.27 | -0.79 | - | |
| Interest & Investment Income | 11.42 | 21.09 | 24.08 | 4.67 | 0.27 | |
| EBT Excluding Unusual Items | -141.22 | -210.3 | -161.34 | -123.32 | -97.26 | |
| Merger & Restructuring Charges | -6.3 | - | - | - | - | |
| Other Unusual Items | -1.83 | - | - | - | - | |
| Pretax Income | -149.34 | -210.3 | -161.34 | -123.32 | -97.26 | |
| Net Income | -149.34 | -210.3 | -161.34 | -123.32 | -97.26 | |
| Net Income to Common | -149.34 | -210.3 | -161.34 | -123.32 | -97.26 | |
| Shares Outstanding (Basic) | 61 | 61 | 59 | 42 | 36 | |
| Shares Outstanding (Diluted) | 61 | 61 | 59 | 42 | 36 | |
| Shares Change (YoY) | 1.37% | 3.10% | 39.75% | 17.21% | 67.94% | |
| EPS (Basic) | -2.43 | -3.47 | -2.75 | -2.94 | -2.71 | |
| EPS (Diluted) | -2.43 | -3.47 | -2.75 | -2.94 | -2.71 | |
| Free Cash Flow | -128.71 | -159.35 | -117.28 | -96.39 | -77.4 | |
| Free Cash Flow Per Share | -2.10 | -2.63 | -2.00 | -2.29 | -2.16 | |
| Gross Margin | - | - | 100.00% | 100.00% | 100.00% | |
| Operating Margin | - | - | -11654.75% | -1313.37% | -1288.10% | |
| Profit Margin | - | - | -10211.14% | -1273.32% | -1284.51% | |
| Free Cash Flow Margin | - | - | -7422.91% | -995.26% | -1022.13% | |
| EBITDA | -148.38 | -226.24 | -182.3 | -125.38 | -96 | |
| D&A For EBITDA | 1.7 | 2.13 | 1.84 | 1.82 | 1.54 | |
| EBIT | -150.07 | -228.37 | -184.15 | -127.2 | -97.54 | |
Source: S&P Capital IQ. Standard template.
Financial Sources.